{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.07","upperLimit":"4.99","value":"2.53"},{"groupId":"OG001","lowerLimit":"1.08","upperLimit":"1.64","value":"1.31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"156"}],"units":"Participants"}],"description":"All randomized subjects were assessed for event-free survival (EFS). EFS was defined as the time from study randomization to the date of induction treatment failure (persistent disease), relapse from CR or CRi or death from any cause, whichever came first. Subjects alive and not known to have any of these events were censored on thee date they were last examined on study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.","id":"OG000","title":"Arm A (CPX-351)"},{"description":"Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.","id":"OG001","title":"Arm B (7+3)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population: All participants randomized in the study.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date that persistent disease was documented or the date of relapse after CR or death, whichever came first","title":"Event-free Survival","type":"SECONDARY","unitOfMeasure":"months"}